Immunotherapy, particularly immune checkpoint inhibitors (ICIs) like PD‐1/PD‐L1 inhibitors, has significantly improved survival rates for some patients, enhancing the body's anti‐tumor immune response by lifting immune suppression on tumor cells [10]. Here, PDCD1 is linked to neoplasm.